References

Syndromes of thrombotic microangiopathy

10.1056/nejmra1312353 · 2014 · External reference

Defective complement inhibitory function predisposes to renal disease

10.1146/annurev-med-072211-110606 · 2013 · External reference

An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group

10.1016/j.kint.2024.05.021 · 2024 · External reference

Complement dysregulation and disease: insights from contemporary genetics

10.1146/annurev-pathol-012615-044145 · 2017 · External reference

Complement activation in secondary thrombotic microangiopathies

10.1093/ndt/gfaf091 · 2025 · External reference

Complement in secondary thrombotic microangiopathy

10.1016/j.ekir.2020.10.009 · 2021 · External reference

Differentiating and managing rare thrombotic microangiopathies during pregnancy and postpartum

10.1097/aog.0000000000005024 · 2023 · External reference

Differentiating hemolysis, elevated liver enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period

10.1161/hypertensionaha.121.17311 · 2021 · External reference

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

10.1371/journal.pone.0010208 · 2010 · External reference

Thrombotic microangiopathies of pregnancy: differential diagnosis

10.1016/j.preghy.2018.02.007 · 2018 · External reference

Thrombotic microangiopathy in pregnancy: current understanding and management strategies

10.1016/j.ekir.2024.05.016 · 2024 · External reference

Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes

10.1182/blood-2014-02-553131 · 2014 · External reference

HELLP syndrome and differential diagnosis with other thrombotic microangiopathies in pregnancy

10.3390/diagnostics14040352 · 2024 · External reference

Pregnancy as a susceptible state for thrombotic microangiopathies

10.3389/fmed.2024.1343060 · 2024 · External reference

Syndromes of thrombotic microangiopathy associated with pregnancy

10.1182/asheducation-2015.1.644 · 2015 · External reference

Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006

10.1016/j.ajog.2008.03.011 · 2008 · External reference

Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition

2023 · External reference

Diagnosis of HELLP syndrome: a 10-year survey in a perinatology centre

10.3390/ijerph16010109 · 2019 · External reference

Circulating angiogenic factor levels in hypertensive disorders of pregnancy

10.1056/evidoa2200161 · 2022 · External reference

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

10.1038/gim.2015.30 · 2015 · External reference

Pulling the trigger in atypical hemolytic uremic syndrome: the role of pregnancy

10.1681/asn.2010030308 · 2010 · External reference

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a global aHUS registry analysis

10.1007/s40620-021-01025-x · 2021 · External reference

Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations

10.1681/asn.2009070706 · 2010 · External reference

The complement system in COVID-19: friend and foe?

10.1172/jci.insight.140711 · 2020 · External reference

Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes

10.1093/ckj/sfab005 · 2021 · External reference

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

10.1182/blood.2020009280 · 2021 · External reference

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

10.1007/s00467-018-4091-3 · 2019 · External reference

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial

10.1016/j.lanepe.2025.101392 · 2025 · External reference

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation

10.2215/cjn.06440616 · 2017 · External reference

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal

10.1093/ckj/sfaa241 · 2021 · External reference

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

10.1182/blood-2005-10-007252 · 2006 · External reference

Familial risk of developing atypical hemolytic-uremic syndrome

10.1182/blood.2020006931 · 2020 · External reference

Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32

10.1093/hmg/ddi066 · 2005 · External reference

Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects

10.1155/2012/370426 · 2012 · External reference

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype

10.1681/asn.2012090884 · 2013 · External reference

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome

10.1016/j.kint.2018.02.029 · 2018 · External reference

A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome

10.1016/j.kint.2017.06.022 · 2018 · External reference

Successful subsequent pregnancy in a woman receiving eculizumab for pregnancy-associated atypical haemolytic uraemic syndrome

2019 · External reference

Eculizumab maintenance and the prevention of atypical hemolytic uremic syndrome relapse during pregnancy: a case report

10.14740/jmc3397 · 2019 · External reference

Eculizumab in early-stage pregnancy

10.1016/j.ekir.2020.09.045 · 2020 · External reference

Eculizumab in pregnancy: a narrative overview

10.1007/s40620-018-0517-z · 2019 · External reference

Pregnancy in women with atypical hemolytic uremic syndrome

10.1159/000518171 · 2022 · External reference

Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria

10.1056/nejmoa1502950 · 2015 · External reference

Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report

10.1136/bmjno-2025-001286 · 2025 · External reference

Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy

10.1182/bloodadvances.2025019253 · 2026 · External reference

The extended use of eculizumab in pregnancy and complement activation–associated diseases affecting maternal, fetal and neonatal kidneys—the future is now?

10.3390/jcm8030407 · 2019 · External reference

Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments

10.1016/j.kint.2025.09.033 · 2026 · External reference

Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities

10.1016/j.kint.2016.12.009 · 2017 · External reference

Thrombotic microangiopathy in patients with malignant hypertension

10.1093/ndt/gfac248 · 2023 · External reference

Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases

10.1111/imr.13131 · 2023 · External reference

Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis

2016 · External reference

Expert statements on the standard of care in critically Ill adult patients with atypical hemolytic uremic syndrome

10.1016/j.chest.2017.03.055 · 2017 · External reference

Thrombotic microangiopathy after kidney transplantation: insights into genetic etiology and clinical outcomes

10.1016/j.ekir.2025.01.026 · 2025 · External reference

Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post-C5 inhibitor era

10.1016/j.ajt.2025.08.019 · 2026 · External reference

De novo thrombotic microangiopathy after kidney transplantation in adults: interplay between complement genetics and multiple endothelial injury

10.1016/j.ajt.2024.01.029 · 2024 · External reference

Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology

10.1186/s12882-023-03326-8 · 2023 · External reference

Post-transplant thrombotic microangiopathy

10.1681/asn.0000000645 · 2025 · External reference

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy

10.1182/hematology.2024000543 · 2024 · External reference

Genetic evaluation of living kidney donor candidates: a review and recommendations for best practices

10.1016/j.ajt.2023.02.020 · 2023 · External reference

Evaluation for genetic disease in kidney transplant candidates: A practice resource

10.1016/j.ajt.2024.10.019 · 2025 · External reference

Kidney transplantation in patients with aHUS: a comparison of eculizumab prophylaxis versus rescue therapy

10.1097/tp.0000000000005135 · 2025 · External reference

The role of complement in kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

10.1016/j.kint.2024.05.015 · 2024 · External reference

Modified Ham test for atypical hemolytic uremic syndrome

10.1182/blood-2015-02-629683 · 2015 · External reference

Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy

10.1182/blood.2024025850 · 2024 · External reference

Ex vivo C5b-9 deposition test to monitor complement activity in clinical and subclinical atypical hemolytic uremic syndrome and in transplantation-associated thrombotic microangiopathy

10.1016/j.ekir.2024.04.022 · 2024 · External reference

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

10.1182/blood-2014-02-558296 · 2014 · External reference

Complement alternative pathway dominance in atypical hemolytic uremic syndrome revealed by endothelial bioassays

10.1016/j.ekir.2025.103717 · 2026 · External reference

Ex vivo test of complement dysregulation in atypical hemolytic uremic syndrome kidney transplant patients: a pilot study

10.1016/j.ekir.2023.10.003 · 2024 · External reference

Ex vivo test for measuring complement attack on endothelial cells: from research to bedside

10.3389/fimmu.2022.860689 · 2022 · External reference